Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18900166 | 0.85 | SORT1 (0.50) | SORT1ALDH1A1LMNASMN1; SMN2GRM5 | |
| SCHEMBL17202119 | 0.81 | ALDH1A1 (0.45) | ALDH1A1EGFRGAALMNASMN1; SMN2 | |
| SCHEMBL20068960 | 0.79 | SORT1 (0.54) | SORT1GAALMNAKDM4EGRM5 | |
| SCHEMBL30440556 | 0.77 | RAB9A (0.58) | ALDH1A1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL1431669 | 0.77 | RAB9A (0.58) | ALDH1A1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL2190227 | 0.75 | RAB9A (0.66) | ALDH1A1SMN1; SMN2GRM5MEN1MAPT | |
| SCHEMBL14667358 | 0.75 | CYP1A2 (0.56) | SORT1LMNAKDM4EGRM5RIPK1 | |
| SCHEMBL30440441 | 0.75 | RAB9A (0.66) | ALDH1A1SMN1; SMN2GRM5MEN1MAPT | |
| SCHEMBL21723677 | 0.73 | ALDH1A1 (0.51) | SORT1ALDH1A1EGFRGAALMNA | |
| SCHEMBL8987836 | 0.73 | KMT2A (0.53) | SORT1ALDH1A1SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| CN-102089304-A | Quinuclidine derivatives as M3 muscarinic receptor antagonists | ASTRAZENECA AB | 2011-06-08 | — | — | CN | disclosed |
| EP-2300464-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009138707-A9 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009138707-A9 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | SORT1 4401/4885ALDH1A1 1452/4885EGFR 683/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | SORT1 4258/4885ALDH1A1 1514/4885EGFR 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.